Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 8/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.38 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127215 | 1.00 | GRIK1 (0.46) | GRIK1SLC7A5GRIK2PTGS1SLC7A11 | |
| SCHEMBL1236556 | 0.81 | SLC7A5 (0.46) | GRIK1SLC7A5GRIK2PTGS1SLC7A11 | |
| SCHEMBL935820 | 0.81 | SLC7A5 (0.46) | GRIK1SLC7A5GRIK2PTGS1SLC7A11 | |
| SCHEMBL31215074 | 0.81 | SLC7A5 (0.46) | GRIK1SLC7A5GRIK2PTGS1SLC7A11 | |
| SCHEMBL25661908 | 0.81 | SLC7A5 (0.46) | GRIK1SLC7A5GRIK2PTGS1SLC7A11 | |
| SCHEMBL2265481 | 0.79 | SLC7A5 (0.44) | GRIK1SLC7A5GRIK2PTGS1SLC7A11 | |
| SCHEMBL2265477 | 0.79 | SLC7A5 (0.44) | GRIK1SLC7A5GRIK2PTGS1SLC7A11 | |
| SCHEMBL25564418 | 0.79 | FDPS (0.45) | GRIK1SLC7A5GRIK2PTGS1SLC1A2 | |
| SCHEMBL196695 | 0.78 | SLC7A5 (0.48) | GRIK1SLC7A5GRIK2PTGS1SLC7A11 | |
| SCHEMBL197139 | 0.78 | SLC7A5 (0.48) | GRIK1SLC7A5GRIK2PTGS1SLC7A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9101662-B2 | Compositions with modulating agents | FOAMIX PHARMACEUTICALS LTD. (IL) | 2015-08-11 | — | — | US | claimed |
| US-8795693-B2 | Compositions with modulating agents | FOAMIX LTD. (IL) | 2014-08-05 | — | — | US | claimed |
| EP-2097065-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | Foamix Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| WO-2008152444-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | FOAMIX LTD. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | FOAMIX LTD. (IL) | 2008-08-28 | — | — | US | claimed |
| US-4363815-A | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions | YU RUEY J | 1982-12-14 | — | — | US | claimed |
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| US-20190029941-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | Dermaforce Holdings, LLC | 2019-01-31 | — | — | US | disclosed |
| US-10123960-B2 | Methods for treating of skin conditions with retinoid double conjugate compounds | PCR TECHNOLOGY HOLDINGS, LC (US) | 2018-11-13 | — | — | US | disclosed |
| US-9673030-B2 | Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry | EMORY UNIVERSITY (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160287507-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | Dermaforce Holdings, LLC | 2016-10-06 | — | — | US | disclosed |
| EP-3068495-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | US CosmeceuTechs LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2016-06-02 | — | — | US | disclosed |
| EP-1860441-A2 | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders | The Institute for Ethnomedicine (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1664793-B1 | NEUROTOXIC AMINO ACID OR NEUROTOXIC DERIVATIVE THEREOF ASSOCIATED WITH NEUROLOGICAL DISORDERS | INST ETHNOMEDICINE (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070254315-A1 | SCREENING FOR NEUROTOXIC AMINO ACID ASSOCIATED WITH NEUROLOGICAL DISORDERS | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2007-11-01 | — | — | US | disclosed |
| US-7256002-B2 | Screening for neurotoxic amino acid associated with neurological disorders | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2007-08-14 | — | — | US | disclosed |
| CN-1890377-A | Production of monatin and monatin precursors | CARGILL INC (US) | 2007-01-03 | — | — | CN | disclosed |
| US-20050042686-A1 | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders | NATIONAL TROPICAL BOTANICAL GARDEN | 2005-02-24 | — | — | US | disclosed |
| US-4363815-A | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions | YU RUEY J | 1982-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123960-B2 | Methods for treating of skin conditions with retinoid double conjugate compounds | RARA, LRAT, RARG | GRIK1 3282/4885SLC7A5 1015/4885GRIK2 2943/4885 |
| US-10842784-B2 | Treatment of energy utilization disease | IRS1, SLC2A1, INSR | GRIK1 1848/4885SLC7A5 833/4885GRIK2 1800/4885 |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | CUTA, SLTM, SMO | GRIK1 2104/4885SLC7A5 4410/4885GRIK2 2050/4885 |
| US-20190029941-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | RARA, RARG, RXRA | GRIK1 3813/4885SLC7A5 3536/4885GRIK2 3487/4885 |
| US-20160287507-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | RARA, RARG, RXRA | GRIK1 2917/4885SLC7A5 2323/4885GRIK2 2789/4885 |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | IRS1, SLC2A1, INSR | GRIK1 1848/4885SLC7A5 833/4885GRIK2 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.